Docstoc
EXCLUSIVE OFFER FOR DOCSTOC USERS
Try the all-new QuickBooks Online for FREE.  No credit card required.

Eurobank

Document Sample
Eurobank Powered By Docstoc
					                       www.eurotansplantbank.org.uk




   EUROPEAN COMMISSION Funded 2001-2004-FP5
                         Project
 Establishment of a cell line and DNA bank for genetic
risk assessment and in vitro post-transplant monitoring
    of complications following allogeneic stem cell
                 transplantation (SCT)
                Acronym: EUROBANK

                   Topic: Research infrastructures
                   Project no: QLRT 2000-000-10



                   The Objective
             This £1.7 (Euro 2.08) million European
             Commission-funded project aims to develop a
             DNA and cell line bank of invaluable use to
             researchers and clinicians in haematopoietic
             stem cell transplant centres throughout
             Europe. Over a period of 3 years, a total of
             300–500 patient and donor cell lines will be
             generated together with 100+ keratinocyte cell
             (skin cell) lines. All cell lines will be
             genotypically characterised for HLA, minor
             histocompatibility antigens and non-HLA
             immunogenetics including cytokine gene
             polymorphisms.
          www.eurotansplantbank.org.uk




         Stem cell transplantation (SCT)         Graft vers us host
         includes the use of bone marrow,        disease occurs when
         cord blood or peripheral blood stem the donor immune
         cells. Curing of patients is            Tcells together with
                                                 the cytokine storm
hampered by complications, including             casuses damage to the
graft versus host disease (GvHD), that           patient. This leads to
arise from genetic differences between           serious pathological
patients and donors. Reducing the SCT-           damage to the skin,
related complications improves the quality       gut and liver
of life. By identifying the genetic
differences between patients and donors,
clinicians will be able to make more accurate
decisions about the donor to be used and or the
type of transplant to be carried out, as well as
the type of therapy to be given. New genetic
risk factors have been identified which can
lead to predicting the outcome of transplants
and there is, therefore, an urgent need for an
accurate assessment of patient genetic risk
(HLA, non-HLA immunogenetics and minor
histocompatiblity differences) in the
   development of SCT-related complications.


            We Aim To…

   Establish a patient and donor DNA and
   immortalised cell line bank, EUROBANK,
   and to register all information on the
   outcome of the transplant. The information
   will then be correlated against the
genetic risk indicators under study,
and factors which may predict
outcome will be assessed. This
research will lead to an individual
‘risk index’ for the patients and may
ultimately become a part of the
clinical pretransplant assessment.
          www.eurotansplantbank.org.uk



EUROBANK will also be of use to multiple
European transplant centres in their research
into transplant related genetic factors. The cell
line and DNA bank, EUROBANK, will be
                based at European SCT
                Centres; co-ordination of
                results will be organised via the
                co-ordinator (Newcastle UK).
                Based on EUROBANK
                research results, it may be
                possible to devise and develop
                new and improved therapeutic
                clinical protocols.
               Benefits
 A pan-European infrastructure co-operation
  network for the exchange of biological
  collections
 A cell and DNA bank for SCT monitoring
  and with potential use to multiple European
  SCT centres
 Based on EUROBANK results, the
  potential to develop new GvHD
  preventative/therapeutic clinical protocols
 Standardisation of methodology for
  immortalisation of cell lines; to develop
  this aspect as a service for other European
  SCT centres.
 Aid in the development of future concepts
  via the study, of non HLA-immunogenetics
  eg, new minor histocompatibility antigens
  and cytokine gene polymorphisms.
            www.eurotansplantbank.org.uk



   Who’s involved
The project involves members of the European
Bone Marrow Transplant (EBMT) Group,
www.ebmt.org, many of whom are committee
members or Chairmen of Working Party
Groups e.g. the Chronic Leukaemia and
Immunobiology Working Parties.
Co-ordinator                   :
Prof Anne Dickinson, University of Newcastle upon
Tyne, UK, Tel/Fax: (0044) 191
2226794Email:a.m.dickinson@ncl.ac.uk

Participants:
Professor Alejandro Madrigal Anthony Nolan
Research Institute, London UK,Email:
madriga@rfhsm.ac.uk
Professor Els Goulmy,Leiden University Medical
Centre,Leiden The Netherlands Email :
e.a.j.m.goulmy@lumc.nl
Dr Gunther Eissner/ Professor E Holle r
Klinikum der Universitat Regensburg, Germany
Email: guenther.eisser@klinik.uni-regensburg.de
Dr Ilona Hromadnikova,
2nd Clinic of Paediatrics,2nd Medical Faculty of
Charles University, Prague, Email:
ilona.hromadnikova@lumc.nl
Professor Eliane Gluckman, Association pour la
Recherche sur les Transplantations Medullaires,
Paris, France. Email: Elaine.gluckman@chu-stlouis.fr
Professor Peter We rnet,Medical School of Heinrich-
Heine University, Email: peter.wernet@uni-
dusseldorf.de
Professor Dominique Charron,15 Rue De L'Ecole
De Medecine,Paris, 75006, France.
Email:charron@ccr.jussie.fr
Professor Hans Joche m Kolb,Klinikum
Großhaden,Ludwig maxillian Universität Munich,
Germany.Email: kolb@med3.med.unimuenchen.de
Prof L Sviland, Haukeland Sykehus, Bergen, Norway
Email: Isvi@haukeland.no
Collaborations Welcomed!!
For further information and participation in the project
access our website and or e-mail the coordinator –
a.m.dickinson@ncl.ac.uk


   www.eurotransplantbank.org.uk

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:13
posted:4/23/2011
language:English
pages:4